Cardiovascular Effects of Angiotensin (1-7) in Essential Hypertension
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to better understand the cardiovascular effects of the
vasodilatory peptide Angiotensin (1-7) in human hypertension. In this study, the
investigators will test the hypothesis that systemic Angiotensin (1-7) infusion produces
negligible effects with intact baroreceptors, and that the cardiovascular effects of this
peptide are unmasked following elimination of baroreflex buffering.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt University
Treatments:
Angiotensin I (1-7) Oxymetazoline Phenylephrine Trimethaphan Trimethaphan camsylate